Lingotto Investment Management LLP Trims Stock Holdings in Tempus AI, Inc. (NASDAQ:TEM)

Lingotto Investment Management LLP reduced its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 16.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 783,859 shares of the company’s stock after selling 150,000 shares during the quarter. Tempus AI comprises 0.7% of Lingotto Investment Management LLP’s investment portfolio, making the stock its 19th biggest position. Lingotto Investment Management LLP’s holdings in Tempus AI were worth $26,463,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. First Horizon Advisors Inc. purchased a new position in Tempus AI during the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC bought a new position in shares of Tempus AI in the fourth quarter valued at approximately $67,000. IFP Advisors Inc purchased a new position in Tempus AI during the fourth quarter valued at approximately $76,000. Vestor Capital LLC bought a new stake in Tempus AI during the 3rd quarter worth approximately $153,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Tempus AI in the 4th quarter worth approximately $178,000. 24.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

TEM has been the topic of several research analyst reports. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a report on Tuesday. Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Bank of America lifted their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Needham & Company LLC upped their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. lowered shares of Tempus AI from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $50.00 to $55.00 in a research report on Tuesday. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average price target of $60.55.

Tempus AI Price Performance

Tempus AI stock opened at $59.10 on Wednesday. The firm has a fifty day simple moving average of $51.28 and a two-hundred day simple moving average of $52.17. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45.

Insider Transactions at Tempus AI

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew Polovin sold 51,504 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at $10,431,543.15. The trade was a 17.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,583,467 shares of company stock worth $130,542,311.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.